HCM
HealthcareHUTCHMED (China) Limited · Drug Manufacturers - Specialty & Generic · $2B
What is HUTCHMED (China) Limited?
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company focused on discovering and commercializing targeted cancer therapies and immunotherapies. Its pipeline spans multiple oncology indications across global markets.
HUTCHMED generates revenue by developing and commercializing small-molecule inhibitors targeting cancer and immunological diseases. Its commercial-stage drugs address conditions including colorectal cancer, lung cancer, and neuroendocrine tumors. The company also earns income through partnerships and licensing arrangements with larger pharmaceutical companies, while continuing to advance a broad clinical pipeline.
HUTCHMED was established in 2016 and is headquartered in Hong Kong.
- Fruquintinib — approved inhibitor for colorectal and other solid tumors
- Savolitinib — targeted therapy for non-small cell lung cancer and renal cell carcinoma
- Surufatinib — inhibitor for neuroendocrine tumors and biliary tract cancer
- Early-stage pipeline including HMPL-523, HMPL-689, and HMPL-760
Is HCM a Good Stock to Buy?
UQS Score rates HCM as Below Average overall, reflecting meaningful challenges across several fundamental dimensions.
The Risk pillar stands out as the clearest positive — HUTCHMED carries a Strong risk profile relative to many clinical-stage peers, suggesting a degree of financial resilience. Growth is rated Neutral, indicating the company is progressing but not yet accelerating at a pace that distinguishes it from the broader sector.
Both the Quality and Moat pillars are rated Weak, pointing to limited durable competitive advantages and below-average business quality metrics at this stage. Valuation is rated Elevated, which may give cost-conscious investors pause.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HCM pay dividends?
No — HUTCHMED (China) Limited does not currently pay a dividend.
HUTCHMED does not currently pay a dividend. As a clinical-stage-oriented biopharmaceutical company, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in HCM are typically seeking long-term value from drug approvals and commercialization rather than income.
When does HCM report earnings?
HUTCHMED reports earnings on a regular cadence, consistent with its listings on major exchanges.
The company's results tend to reflect the dual nature of its business — commercial revenue from approved drugs alongside ongoing research and development expenditure. Progress in pipeline milestones and partnership activity often shapes the market's reaction to quarterly updates.
For the most recent quarter's results and guidance, visit HUTCHMED's official investor relations page.
HCM Price History
-50.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in HUTCHMED (China) Limited?
Based on HUTCHMED (China) Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HCM Long-term Outlook
HUTCHMED's fundamental outlook is shaped by a Neutral Growth profile and a Strong Risk rating. The pipeline breadth offers multiple potential catalysts, but the Weak Quality and Moat ratings suggest the company has not yet built the durable earnings power or competitive barriers typical of established pharmaceutical leaders. An Elevated Valuation adds further complexity for investors assessing entry points.
Growth drivers
- Continued global commercialization of Fruquintinib across new indications and markets
- Pipeline advancement of early-stage inhibitors toward clinical readouts
- Licensing and partnership deals that could accelerate revenue without proportional cost increases
Key risks
- Clinical trial failures or regulatory setbacks across the broad pipeline
- Elevated valuation leaving limited margin of safety if growth disappoints
- Competitive pressure from established oncology players with deeper resources
HCM vs Peers
HUTCHMED operates in a competitive specialty pharma and oncology space alongside companies with differing business models and therapeutic focuses.
Curaleaf operates in the cannabis sector rather than traditional oncology, representing a distinct regulatory and commercial environment compared to HUTCHMED's targeted therapeutics focus.
Supernus concentrates on central nervous system disorders, giving it a different therapeutic niche and revenue profile than HUTCHMED's oncology and immunology pipeline.
Bausch Health is a diversified specialty pharma company with an established commercial portfolio, contrasting with HUTCHMED's more pipeline-dependent growth model.
Frequently Asked Questions
What does HUTCHMED do?
HUTCHMED discovers, develops, and commercializes targeted therapies and immunotherapies for cancer and immunological diseases. Its approved drugs include Fruquintinib and Surufatinib, while its pipeline spans numerous early- and mid-stage inhibitors targeting a wide range of oncology indications globally.
Does HCM pay dividends?
No, HUTCHMED does not currently pay a dividend. The company reinvests available capital into its research programs and clinical pipeline. Investors in HCM are generally focused on potential value creation from drug development milestones rather than income distributions.
When does HCM report earnings?
HUTCHMED reports financial results on a regular cadence consistent with its exchange listings. For precise dates and the most recent quarterly results, check HUTCHMED's investor relations page directly, as our data source does not cover specific upcoming earnings dates.
Is HCM a good stock to buy?
UQS Score rates HCM as Below Average overall. The Risk pillar is Strong, but Quality and Moat are both Weak, and Valuation is Elevated. Whether HCM fits your portfolio depends on your risk tolerance and investment thesis around its pipeline. View the full pillar breakdown on UQS Pro.
Is HCM overvalued?
The UQS Valuation pillar for HCM is rated Elevated, suggesting the current market price may not offer a wide margin of safety relative to the company's current fundamental profile. Investors should weigh this against the potential upside from pipeline catalysts.
How does HCM compare to its competitors?
HUTCHMED's peers in the UQS comparison set include Supernus Pharmaceuticals, Bausch Health, and Curaleaf Holdings. Each operates in a different therapeutic or regulatory niche. HUTCHMED is more pipeline-dependent than some peers, which shapes both its growth potential and its risk profile.
What is HCM's market cap bracket?
HUTCHMED is classified as a mid-cap company. This places it in a segment of the market that can offer growth potential beyond large established pharma names, but with less financial scale and resources than mega-cap peers.
Who founded HUTCHMED?
HUTCHMED (China) Limited was established in 2016. It operates as part of the broader CK Hutchison group. For detailed founding history and leadership background, HUTCHMED's official corporate website and investor relations materials are the most reliable sources.
Is HCM a long-term quality investment?
As a long-term quality indicator, HCM's Below Average UQS Score — driven by Weak Quality and Moat ratings — suggests the company has not yet established the durable competitive advantages typically associated with high-quality long-term holdings. Pipeline success could change this picture over time.
What is the main competitive advantage of HUTCHMED?
HUTCHMED's primary differentiator is its China-rooted oncology pipeline with global licensing ambitions. Approved drugs like Fruquintinib provide a commercial foundation, while its broad inhibitor portfolio targets multiple cancer types. However, the UQS Moat pillar is currently rated Weak, indicating these advantages are not yet deeply entrenched.
Unlock Full HCM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for HCM
- ✓Access full financial metrics and quality indicators
- ✓Compare HCM side-by-side with sector peers on every pillar
- ✓Track valuation and risk signals updated regularly
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
HCM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 24, 2026 | 44.2 | 38.3 | 26.0 | 50.2 | 82.4 | 38.4 | -0.1 |
| May 21, 2026 | 44.3 | 38.3 | 26.0 | 50.2 | 82.4 | 38.6 | +0.3 |
| May 17, 2026 | 44.0 | 38.3 | 26.0 | 50.2 | 82.4 | 36.8 | +0.4 |
| May 7, 2026 | 43.6 | 38.3 | 26.0 | 50.2 | 82.4 | 34.3 | -0.1 |
| May 3, 2026 | 43.7 | 38.3 | 26.0 | 50.2 | 82.4 | 34.6 | +0.3 |
| Apr 26, 2026 | 43.4 | 38.3 | 26.0 | 50.2 | 82.4 | 32.9 | +0.5 |
| Apr 19, 2026 | 42.9 | 38.3 | 26.0 | 50.2 | 82.4 | 29.2 | -0.1 |
| Apr 14, 2026 | 43.0 | 38.3 | 26.0 | 50.2 | 82.4 | 30.4 | 0.0 |
| Apr 12, 2026 | 43.0 | 38.3 | 26.0 | 50.2 | 82.4 | 30.2 | 0.0 |
| Apr 5, 2026 | 43.0 | 38.3 | 26.0 | 50.2 | 82.4 | 29.8 | 0.0 |
HCM — Pillar Breakdown
Quality
— 38.3/100 (25%)HUTCHMED (China) Limited has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 50.2/100 (20%)HUTCHMED (China) Limited shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)HUTCHMED (China) Limited carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 38.4/100 (15%)HUTCHMED (China) Limited has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
Moat
— 26/100 (25%)HUTCHMED (China) Limited operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HCM.
Score Composition
Financial Data
More Stock Analysis
How is the HCM UQS Score Calculated?
The UQS (Unified Quality Score) for HUTCHMED (China) Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses HUTCHMED (China) Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether HUTCHMED (China) Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.